AstraZeneca (AstraZeneca) Pre-Tax Income

: $6,899 Mil (TTM As of Dec. 2023) 中文

View and export this data going back to 1993. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. AstraZeneca's pretax income for the three months ended in Dec. 2023 was $897 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $6,899 Mil. AstraZeneca's pretax margin was 7.46%.

During the past 13 years, AstraZeneca's highest Pretax Margin was 15.44%. The lowest was -0.71%. And the median was 9.47%.

AstraZeneca Pre-Tax Income Historical Data

The historical data trend for AstraZeneca's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

1,548.00

3,916.00

-265.00

2,501.00

6,899.00

AstraZeneca Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income																778.00	2,262.00	2,088.00	1,652.00	897.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pre-Tax Income Distribution

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Pre-Tax Income falls into.

AstraZeneca Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

AstraZeneca's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	8722	+	0	+	-1589	+	301	+	-535
	=	6,899

AstraZeneca's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	2004	+	0	+	-408	+	65	+	-764
	=	897

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,899 Mil.

AstraZeneca (NAS:AZN) Pre-Tax Income Explanation

AstraZeneca's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	897	/	12024
	=	7.46%

During the past 13 years, AstraZeneca's highest Pretax Margin was 15.44%. The lowest was -0.71%. And the median was 9.47%.

AstraZeneca Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.